Myalgia in liver transplant recipients after receiving tixagevimab/cilgavimab for pre-exposure prophylaxis of COVID-19: A case series

Transpl Infect Dis. 2022 Dec;24(6):e13932. doi: 10.1111/tid.13932. Epub 2022 Aug 23.

Authors

Hanna L Kleiboeker¹, Margaret R Jorgenson¹, Jeannina A Smith²

Affiliations

¹ Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA.
² Department of Medicine, Division of Infectious Diseases, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Abstract

Keywords: COVID-19; liver transplant; myalgia; tixagevimab/cilgavimab.

MeSH terms

COVID-19* / prevention & control
Humans
Liver Transplantation* / adverse effects
Myalgia
Pre-Exposure Prophylaxis*
Transplant Recipients

Substances

tixagevimab
cilgavimab